Glioblastoma (GBM) is one of the most devastating brain tumors with poor prognosis and high mortality.
Although radical surgical treatment with subsequent radiation and chemotherapy can improve the survival,
the efficacy of such regimens is insufficient because the GBM cells can spread and destroy normal brain structures.
Moreover, these non-specific treatments may damage adjacent healthy brain tissue. It is thus imperative to
develop novel therapies to precisely target invasive tumor cells without damaging normal tissues. Immunotherapy
is a promising approach due to its capability to suppress the growth of various tumors in preclinical model and
clinical trials. Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting
an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated
a satisfactory efficacy in treating malignant brain tumors. Here we summarize the recent progresses in
immunotherapeutic strategy using CAR-modified T cells oriented to EGFRvIII against GBM.
Keywords: EGFRvIII, chimeric antigen receptor, adoptive cell therapy, glioblastoma.
open access plus
Rights & PermissionsPrintExport